Streetwise Live! Presents Cross River Ventures on 07/28/2021. Learn More

Streetwise Articles



Cannabis Market Delivering for Consumers and Investors
Source: Streetwise Reports  (7/21/21)
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value. More >


Coverage Initiated on Company with a 'Genuine Physiological Heart Replacement Therapy'
Source: Streetwise Reports  (7/21/21)
The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report. More >


Biopharma Partners with NIH to Advance Women's Hormone-Free Contraceptive
Source: Streetwise Reports  (7/21/21)
A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience. More >


Rapidly Growing Virtual Healthcare Firm Adds Three New US Group Medical Practice Clients
Source: Streetwise Reports  (7/21/21)
Reliq Health Technologies advised it entered into agreements with three physician practices in Texas for its iUGO Care platform. More >


HCA Healthcare Shares Gain 15% on Strong Q2 Performance and Raised FY Outlook
Source: Streetwise Reports  (7/20/21)
HCA Healthcare shares established a new 52-week high after the company reported a greater than 30% increase in YoY revenue in Q2/21. More >


Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant
Source: Streetwise Reports  (7/20/21)
Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets. More >


Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data
Source: Streetwise Reports  (7/19/21)
Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial. More >


Zynex Shares Rise as Firm Notches Significant Q2 Order Growth and Raises EBITDA Outlook
Source: Streetwise Reports  (7/16/21)
Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million. More >


Merger of Two Biopharmas 'Brings a New Dawn'
Source: Streetwise Reports  (7/14/21)
The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report. More >


FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design
Source: Streetwise Reports  (7/14/21)
The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report. More >


 McAlinden Research Partners

US Cannabis Sales Hold Strong as Industry Lays Out New Lobbying Efforts to Expedite Federal Reform
Source: McAlinden Research for Streetwise Reports  (7/14/21)
McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when." More >


Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2
Source: Streetwise Reports  (7/12/21)
Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue. More >


Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery
Source: Streetwise Reports  (7/9/21)
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke. More >


Biopharma Files New Drug Application for Lead Clinical Product
Source: Streetwise Reports  (7/7/21)
A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report. More >


Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity
Source: Streetwise Reports  (7/7/21)
The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report. More >


Biohaven Posts Revenue of $93 Million in Q2 for Its Migraine Medicine
Source: Streetwise Reports  (7/7/21)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment. More >


ALX Oncology Shares Rise on Positive Response and Survival Data in Phase 1b Gastric Cancer Trial
Source: Streetwise Reports  (7/6/21)
Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer. More >


Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases
Source: Streetwise Reports  (7/2/21)
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. More >


Pulse Bio Shares Beat Higher on Launch of CellFX NPS System in Canada
Source: Streetwise Reports  (7/1/21)
Pulse Biosciences shares traded 27% higher after the company announced it secured a $50 million private placement one day after it reported the first CellFX® procedure using its proprietary Nano-Pulse Stimulation technology had been performed in Canada. More >


Coverage Initiated on Developer of Psychedelic Drugs for PTSD, Smoking Cessation
Source: Streetwise Reports  (6/30/21)
The investment thesis for Mydecine Innovations Group is presented in a ROTH Capital Partners report. More >


Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke
Source: Streetwise Reports  (6/30/21)
Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency. More >


Biotech Takes a 'Disruptive Drug Development Approach' to Destroy Dysregulated Transcription in Cancer
Source: Streetwise Reports  (6/30/21)
Kronos Bio's key assets are reviewed in an H.C. Wainwright & Co. report. More >


Cerevel Shares More Than Double on Positive Topline Results in Phase 1b Schizophrenia Trial
Source: Streetwise Reports  (6/29/21)
Shares of Cerevel Therapeutics hit a new 52-week high after the company released positive topline results for its CVL-231 in a Phase 1b clinical trial in schizophrenia patients. More >


Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial
Source: Streetwise Reports  (6/28/21)
Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis.


More >


Eli Lilly Receives FDA Breakthrough Therapy Designation for Alzheimer's Treatment
Source: Streetwise Reports  (6/24/21)
Eli Lilly and Co's shares traded 8% higher and reached a new 52-week high after the company reported the FDA granted its investigational antibody therapy donanemab Breakthrough Therapy designation for use in treating Alzheimer's disease. More >


Showing Results: 1 to 25 of 1854 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts